# Telenursing Health Education and Lifestyle Modification Among Patients With Diabetes in Bangladesh: Protocol for a Pilot Study With a Quasi-experimental Pre- and Postintervention Design

**Authors:** Michiko Moriyama, K A T M Ehsanul Huq, Lucy Mondol, Akhi Roy Mita, Niru Shamsun Nahar

PMC · DOI: 10.2196/71849 · JMIR Research Protocols · 2025-05-09

## TL;DR

This pilot study in Bangladesh tests a telenursing program to improve diabetes management through health education and lifestyle changes.

## Contribution

The study introduces a self-management telenursing program tailored for diabetes patients in a low-resource setting.

## Key findings

- The telenursing program aims to improve diabetes control by enhancing self-management skills.
- The study will assess the feasibility and efficacy of the program in a real-world setting.
- Data collection is complete, with results expected to be published in 2026.

## Abstract

The global burden of chronic diseases is increasing and becoming a public health issue throughout the world. The use of telenursing is increasing significantly during and after the COVID-19 pandemic to treat and prevent chronic diseases. Telenursing is growing in many countries to reduce health care costs, increase the number of aging and chronically ill populations, and increase health care coverage to distant, rural, small, or sporadically populated regions. Among its many benefits, telenursing may help to solve increasing shortages of nurses, reduce distances, save travel time, and keep patients out of the hospital.

The objective of this study is to apply the self-management telenursing program and telenursing system developed by the researchers to Bangladesh and to evaluate its feasibility and efficacy (improved diabetes control in participants).

This is a pilot, quasi-experimental pre- and post-intervention study. Diabetes patients who will attend the Grameen Primary Health Centers (PHCs) in Bangladesh will be enrolled between September 2024 and August 2025. We include patients who have been diagnosed with type 2 diabetes, both sexes, ages 18-75 years old, all types of treatment, willing to participate and give us consent. We exclude patients who have been diagnosed with gestational diabetes, diabetes as a secondary cause, complication of chronic kidney disease (CKD) stage 5, Hemoglobin A1c (HbA1c) is less than 7% for the past 1 year with CKD stage 1 or 2, no complications or complications with good control, having enough knowledge (had education before) and implemented good practice regarding diabetes management assessed by the research nurses, and disabled persons who need other person’s support for daily living. The sample size was calculated and found 70. Written informed consent will be obtained from all the participants. The study protocol got approval from the National Research Ethics Committee of the Bangladesh Medical Research Council (BMRC/NREC/2022-2025/336) on September 08, 2024. The outcome of this study is to evaluate the effects of telenursing intervention by controlling HbA1c.

The project was funded in 2024. The enrollment of the participants started on October 26, 2024, and the required sample (n=70) enrollment was completed in February 2025. Data analysis will be started after completion of data collection and results will be expected to be submitted for publication in 2026.

Diabetic patients will acquire disease-specific management skills. Setting and monitoring goals ensures the continuation of the desired behavior and gives the patients control over their lifestyle. After developing self-management skills, patients assess their lab data and lifestyles including diet, and understand their condition so that they can work with their physiological data by acquiring knowledge of both the disease and self-care. By making self-supported decisions, the patients will be able to manage their diet, exercise, and medication.

ClinicalTrials.gov NCT06632652; https://clinicaltrials.gov/study/NCT06632652

DERR1-10.2196/71849

## Linked entities

- **Diseases:** diabetes (MONDO:0005015), type 2 diabetes (MONDO:0005148), gestational diabetes (MONDO:0005406)

## Full-text entities

- **Diseases:** type 2 diabetes (MESH:D003924), Diabetes (MESH:D003920), COVID-19 (MESH:D000086382), CKD (MESH:D051436), chronically (MESH:D002908), gestational diabetes (MESH:D016640)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12102625/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12102625/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12102625/full.md

---
Source: https://tomesphere.com/paper/PMC12102625